93 related articles for article (PubMed ID: 38730475)
1. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
[TBL] [Abstract][Full Text] [Related]
2. Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer.
Zhang T; Bai L; You R; Yang M; Chen Q; Cheng Y; Qian Z; Wang Y; Liu Y
J Mater Chem B; 2024 Jun; 12(22):5465-5478. PubMed ID: 38742364
[TBL] [Abstract][Full Text] [Related]
3. Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.
Carney CP; Kapur A; Anastasiadis P; Ritzel RM; Chen C; Woodworth GF; Winkles JA; Kim AJ
Mol Pharm; 2023 Jan; 20(1):314-330. PubMed ID: 36374573
[TBL] [Abstract][Full Text] [Related]
4. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.
Wang R; Huang X; Chen X; Zhang Y
ACS Biomater Sci Eng; 2024 Jun; 10(6):3568-3598. PubMed ID: 38815129
[TBL] [Abstract][Full Text] [Related]
6. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.
Onkar SS; Carleton NM; Lucas PC; Bruno TC; Lee AV; Vignali DAA; Oesterreich S
Cancer Discov; 2023 Jan; 13(1):23-40. PubMed ID: 36620880
[TBL] [Abstract][Full Text] [Related]
7. T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies.
Ozsoy F; Mohammed M; Jan N; Lulek E; Ertas YN
ACS Appl Bio Mater; 2024 May; 7(5):2637-2659. PubMed ID: 38687958
[TBL] [Abstract][Full Text] [Related]
8. Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.
Jiang Y; Krishnan N; Zhou J; Chekuri S; Wei X; Kroll AV; Yu CL; Duan Y; Gao W; Fang RH; Zhang L
Adv Mater; 2020 Jul; 32(30):e2001808. PubMed ID: 32538494
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy, Antiangiogenesis and Immunotherapy.
Lan J; Chen L; Li Z; Liu L; Zeng R; He Y; Shen Y; Zhang T; Ding Y
Adv Healthc Mater; 2024 May; ():e2400046. PubMed ID: 38767575
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible cellulose nanocrystal-based Trojan horse enables targeted delivery of nano-Au radiosensitizers to triple negative breast cancer cells.
Biagiotti G; Cazzoli R; Andreozzi P; Aresta G; Francesco M; Mangini C; di Gianvincenzo P; Tobia C; Recchia S; Polito L; Severi M; Vittorio O; Cicchi S; Moya SE; Ronca R; Albini A; Berti D; Orecchia R; Garibaldi C; Minucci S; Richichi B
Nanoscale Horiz; 2024 May; ():. PubMed ID: 38775782
[TBL] [Abstract][Full Text] [Related]
11. Plant-Derived Vesicle-like Nanoparticles: The Next-Generation Drug Delivery Nanoplatforms.
Wang X; Xin C; Zhou Y; Sun T
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794248
[TBL] [Abstract][Full Text] [Related]
12. Janus Nanoparticles for T Cell Activation: Clustering Ligands to Enhance Stimulation.
Lee K; Yu Y
J Mater Chem B; 2017 Jun; 5(23):4410-4415. PubMed ID: 28966791
[TBL] [Abstract][Full Text] [Related]
13. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
Blaya-Cánovas JL; Griñán-Lisón C; Blancas I; Marchal JA; Ramírez-Tortosa C; López-Tejada A; Benabdellah K; Cortijo-Gutiérrez M; Cano-Cortés MV; Graván P; Navarro-Marchal SA; Gómez-Morales J; Delgado-Almenta V; Calahorra J; Agudo-Lera M; Sagarzazu A; Rodríguez-González CJ; Gallart-Aragón T; Eich C; Sánchez-Martín RM; Granados-Principal S
Mol Cancer; 2024 May; 23(1):83. PubMed ID: 38730475
[TBL] [Abstract][Full Text] [Related]
14. Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment.
Jin Y; Huang Y; Ren H; Huang H; Lai C; Wang W; Tong Z; Zhang H; Wu W; Liu C; Bao X; Fang W; Li H; Zhao P; Dai X
Biomaterials; 2024 Mar; 305():122463. PubMed ID: 38232643
[TBL] [Abstract][Full Text] [Related]
15. A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering.
Krishnan N; Jiang Y; Zhou J; Mohapatra A; Peng FX; Duan Y; Holay M; Chekuri S; Guo Z; Gao W; Fang RH; Zhang L
Nat Nanotechnol; 2024 Mar; 19(3):345-353. PubMed ID: 37903891
[TBL] [Abstract][Full Text] [Related]
16. In vitro modeling of CD8
Wu JE; Manne S; Ngiow SF; Baxter AE; Huang H; Freilich E; Clark ML; Lee JH; Chen Z; Khan O; Staupe RP; Huang YJ; Shi J; Giles JR; Wherry EJ
Sci Immunol; 2023 Aug; 8(86):eade3369. PubMed ID: 37595022
[TBL] [Abstract][Full Text] [Related]
17. Chemo-Immunotherapy: A New Trend in Cancer Treatment.
Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Martínez-Pérez A; Rodrigo JP; García-Pedrero JM; Gonzalez S
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296876
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
